Novel Approaches to Possible Targeted Therapies and Prophylaxis of Uterine Fibroids
Uterine leiomyomas are the most common benign tumors in women of childbearing age. They may lead to problems of conception or complications during the gestational period. The methods of treatment include surgical (myomectomy and hysterectomy, embolization of arteries) and therapeutic treatment (ulipristal acetate, leuprolide acetate, cetrorelix, goserelin, mifepristone). Both approaches are efficient but incompatible with pregnancy planning. Therefore, there is a call for medical practice to develop therapeutical means of preventing leiomyoma onset in patients planning on becoming pregnant. Based on the analysis of GWAS data on the search for mononucleotide polymorphisms associated with the risk of leiomyoma, in meta-transcriptomic and meta-methylomic studies, target proteins have been proposed. Prospective therapeutic treatments of leiomyoma may be based on chemical compounds, humanized recombinant antibodies, vaccines based on markers of the uterine leiomyoma cells that are absent in the adult organism, or DNA and RNA preparations. Three different nosological forms of the disease associated with driver mutations in the MED12, HMGA2, and FH genes should be considered when developing or prescribing drugs. For example, synthetic inhibitors and vaccines based on matrix metalloproteinases MMP11 and MMP16 are expected to be effective only for the prevention of the occurrence of MED12-dependent nodules.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Diseases (Basel, Switzerland) - 11(2023), 4 vom: 01. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kuznetsova, Maria V [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Fibroid |
|---|
| Anmerkungen: |
Date Revised 23.11.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/diseases11040156 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364786582 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364786582 | ||
| 003 | DE-627 | ||
| 005 | 20231226100153.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/diseases11040156 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1215.xml |
| 035 | |a (DE-627)NLM364786582 | ||
| 035 | |a (NLM)37987267 | ||
| 035 | |a (PII)156 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kuznetsova, Maria V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel Approaches to Possible Targeted Therapies and Prophylaxis of Uterine Fibroids |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 23.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Uterine leiomyomas are the most common benign tumors in women of childbearing age. They may lead to problems of conception or complications during the gestational period. The methods of treatment include surgical (myomectomy and hysterectomy, embolization of arteries) and therapeutic treatment (ulipristal acetate, leuprolide acetate, cetrorelix, goserelin, mifepristone). Both approaches are efficient but incompatible with pregnancy planning. Therefore, there is a call for medical practice to develop therapeutical means of preventing leiomyoma onset in patients planning on becoming pregnant. Based on the analysis of GWAS data on the search for mononucleotide polymorphisms associated with the risk of leiomyoma, in meta-transcriptomic and meta-methylomic studies, target proteins have been proposed. Prospective therapeutic treatments of leiomyoma may be based on chemical compounds, humanized recombinant antibodies, vaccines based on markers of the uterine leiomyoma cells that are absent in the adult organism, or DNA and RNA preparations. Three different nosological forms of the disease associated with driver mutations in the MED12, HMGA2, and FH genes should be considered when developing or prescribing drugs. For example, synthetic inhibitors and vaccines based on matrix metalloproteinases MMP11 and MMP16 are expected to be effective only for the prevention of the occurrence of MED12-dependent nodules | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a HMGA2 | |
| 650 | 4 | |a IL17B | |
| 650 | 4 | |a MED12 | |
| 650 | 4 | |a MMP11 | |
| 650 | 4 | |a MMP16 | |
| 650 | 4 | |a fibroid | |
| 650 | 4 | |a fumarate hydratase | |
| 650 | 4 | |a humanized antibodies | |
| 650 | 4 | |a inhibitors | |
| 650 | 4 | |a pregnancy | |
| 650 | 4 | |a targets | |
| 650 | 4 | |a therapy | |
| 650 | 4 | |a uterine leiomyoma | |
| 650 | 4 | |a vaccines | |
| 700 | 1 | |a Tonoyan, Narine M |e verfasserin |4 aut | |
| 700 | 1 | |a Trubnikova, Elena V |e verfasserin |4 aut | |
| 700 | 1 | |a Zelensky, Dmitry V |e verfasserin |4 aut | |
| 700 | 1 | |a Svirepova, Ksenia A |e verfasserin |4 aut | |
| 700 | 1 | |a Adamyan, Leila V |e verfasserin |4 aut | |
| 700 | 1 | |a Trofimov, Dmitry Y |e verfasserin |4 aut | |
| 700 | 1 | |a Sukhikh, Gennady T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diseases (Basel, Switzerland) |d 2013 |g 11(2023), 4 vom: 01. Nov. |w (DE-627)NLM242728715 |x 2079-9721 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2023 |g number:4 |g day:01 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/diseases11040156 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2023 |e 4 |b 01 |c 11 | ||